Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Saccharomyces Boulardii wins 3 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Likely helps
13 of 15 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (1)
Outcomes where both Agarikon and Saccharomyces Boulardii have evidence — compare verdict strength side-by-side.
500-1500mg extract daily
With or without food
Agarikon extract
250-500mg (5-10 billion CFU) daily
With or without food, At least 2 hours away from antifungals
Capsules (lyophilized)
4-8 weeks
Ongoing
N/A
During use
1-3 days
1-2 weeks
Fomitopsis officinalis: a Species of Arboreal Mushroom with Promising Biological and Medicinal Properties
Chemistry & biodiversity (2020) · Systematic review
Because of its valuable biological properties and its use in 18th and 19th-century pharmacy, Fomitopsis officinalis used to be mass-collected.
An antitumor fungal polysaccharide from Fomitopsis officinalis by activating immunity and inhibiting angiogenesis
International journal of biological macromolecules (2024) · Observational
The following mechanism examination discovered that FOBP50-1 interacted with TLR-4, PD-1, and VEGF to activate immunity and inhibit angiogenesis according to a series of cell, transgenic zebrafish, and surface plasmon resonance (SPR) experiments.
A fungal polysaccharide from Fomitopsis officinalis as a multi-target molecule to combat cancer
International journal of biological macromolecules (2024) · Observational
The following mechanistic analysis discovered that the in vivo antitumor effect was linked to immune activation and angiogenesis inhibition.
Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication of Helicobacter pylori: a meta-analysis
Frontiers in cellular and infection microbiology (2025) · Meta analysis · n=5036
S. boulardii supplementation in traditional eradication therapy significantly improves the H. pylori eradication rate and reduces the total adverse effects and incidence of diarrhea, bloating, constipation, and nausea.
Probiotics for treating acute infectious diarrhoea
The Cochrane database of systematic reviews (2020) · Meta analysis · n=12127
Effect size was similar in the sensitivity analysis and marked heterogeneity persisted.
The use of probiotics and prebiotics in decolonizing pathogenic bacteria from the gut; a systematic review and meta-analysis of clinical outcomes
Gut microbes (2024) · Meta analysis · n=2871
This review aims to analyze available evidence from human-controlled trials to determine the effect size of probiotic interventions in decolonizing AMR pathogenic bacteria from the gut.
Evidence primarily from animal studies and in-vitro research. Polysaccharide compounds show immunomodulatory activity through TLR-4 interactions. Human clinical data limited. Conservative estimates due to lack of RCT data.
Based on multiple meta-analyses showing 1.1-1.6 day reduction in diarrhea duration. Effect size appears to plateau at standard therapeutic doses. Limited data on doses above 20 billion CFU.
AI-estimated from published studies. Interpret as directional guidance.
Saccharomyces Boulardii has a higher evidence score (8.5/10 vs 3.5/10) and wins in 3 of 3 categories.
For reduce inflammation, Saccharomyces Boulardii has a higher relevance score (90 vs 45).
No known interactions between Agarikon and Saccharomyces Boulardii have been documented in our database. However, always consult a healthcare provider before combining supplements.